The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities

2.50
Hdl Handle:
http://hdl.handle.net/2336/3495
Title:
The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities
Authors:
Hansdottir, Helga; Franzson, Leifur; Prestwood, Karen; Sigurdsson, Gunnar
Citation:
J Am Geriatr Soc 2004, 52(5):779-83
Issue Date:
2004
Abstract:
OBJECTIVES: To examine the effect of raloxifene on bone turnover in elderly women. DESIGN: Clinical intervention. SETTING: Long-term care facilities. PARTICIPANTS: Nineteen women completed the study, mean age 85 (range 76-99). INTERVENTION: Raloxifene 60 mg was given daily for 12 weeks. MEASUREMENTS: Markers of bone turnover were plasma C-telopeptides of type I collagen (CTx), urine cross-linked N-telopeptides of type I collagen (NTx) and serum tartrate-resistant acid phosphatase (TRAP 5b), plasma osteocalcin, and serum bone alkaline phosphatase. Other markers were serum 25-OH vitamin D, parathyroid hormone, ionized calcium, and phosphate. Markers were measured at baseline, after calcium and vitamin D had been taken for 6 weeks, after raloxifene had been taken for 12 weeks, and 6 weeks after raloxifene had been stopped. Paired sample t test was used to examine changes in markers at each time point. RESULTS: Plasma CTx decreased on average by 31%, urinary NTx by 35%, plasma osteocalcin by 25%, serum bone alkaline phosphatase by 15% (P<.01), and serum TRAP 5b by 10% (P<.05) on treatment. CONCLUSION: Raloxifene reduces bone turnover in elderly women living in long-term care facilities. The effect of raloxifene on bone turnover is comparable with that seen in younger postmenopausal women.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1532-5415.2004.52218.x

Full metadata record

DC FieldValue Language
dc.contributor.authorHansdottir, Helga-
dc.contributor.authorFranzson, Leifur-
dc.contributor.authorPrestwood, Karen-
dc.contributor.authorSigurdsson, Gunnar-
dc.date.accessioned2006-07-19T11:33:43Z-
dc.date.available2006-07-19T11:33:43Z-
dc.date.issued2004-
dc.identifier.citationJ Am Geriatr Soc 2004, 52(5):779-83en
dc.identifier.issn0002-8614-
dc.identifier.pmid15086661-
dc.identifier.doi10.1111/j.1532-5415.2004.52218.x-
dc.identifier.otherEND12en
dc.identifier.otherGER12en
dc.identifier.urihttp://hdl.handle.net/2336/3495-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractOBJECTIVES: To examine the effect of raloxifene on bone turnover in elderly women. DESIGN: Clinical intervention. SETTING: Long-term care facilities. PARTICIPANTS: Nineteen women completed the study, mean age 85 (range 76-99). INTERVENTION: Raloxifene 60 mg was given daily for 12 weeks. MEASUREMENTS: Markers of bone turnover were plasma C-telopeptides of type I collagen (CTx), urine cross-linked N-telopeptides of type I collagen (NTx) and serum tartrate-resistant acid phosphatase (TRAP 5b), plasma osteocalcin, and serum bone alkaline phosphatase. Other markers were serum 25-OH vitamin D, parathyroid hormone, ionized calcium, and phosphate. Markers were measured at baseline, after calcium and vitamin D had been taken for 6 weeks, after raloxifene had been taken for 12 weeks, and 6 weeks after raloxifene had been stopped. Paired sample t test was used to examine changes in markers at each time point. RESULTS: Plasma CTx decreased on average by 31%, urinary NTx by 35%, plasma osteocalcin by 25%, serum bone alkaline phosphatase by 15% (P<.01), and serum TRAP 5b by 10% (P<.05) on treatment. CONCLUSION: Raloxifene reduces bone turnover in elderly women living in long-term care facilities. The effect of raloxifene on bone turnover is comparable with that seen in younger postmenopausal women.en
dc.language.isoenen
dc.publisherBlackwellen
dc.relation.urlhttp://www.blackwell-synergy.com/doi/abs/10.1111/j.1532-5415.2004.52218.xen
dc.subjectAcid Phosphataseen
dc.subjectAge Factorsen
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAlkaline Phosphataseen
dc.subjectBiological Markersen
dc.subjectBone Densityen
dc.subjectBone Remodelingen
dc.subjectBone and Bonesen
dc.subjectCalciumen
dc.subjectCollagen Type Ien
dc.subjectComparative Studyen
dc.subjectData Interpretation, Statisticalen
dc.subjectFemaleen
dc.subjectFractures, Boneen
dc.subjectHumansen
dc.subjectLong-Term Careen
dc.subjectNursing Homesen
dc.subjectOsteocalcinen
dc.subjectOsteoporosis, Postmenopausalen
dc.subjectParathyroid Hormoneen
dc.subjectPhosphatesen
dc.subjectResearch Support, Non-U.S. Gov'ten
dc.subjectRisk Factorsen
dc.subjectSelective Estrogen Receptor Modulatorsen
dc.subjectSex Factorsen
dc.subjectTime Factorsen
dc.subjectVitamin Den
dc.subject.meshRaloxifeneen
dc.titleThe effect of raloxifene on markers of bone turnover in older women living in long-term care facilitiesen
dc.typeArticleen
dc.identifier.journalJournal of the American Geriatrics Societyen
dc.format.digYES-
All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.